A Phase I Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-386 With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers

Chong Kun Dang Pharmaceutical1 site in 1 country31 target enrollmentSeptember 23, 2022

ConditionsHypertension and Dyslipidemia

InterventionsCKD-386(4) F2 CKD-386(4) F1 D013, D326, D337

DrugsCKD-386(4) F1 CKD-386(4) F2 D013, D326, D337

Overview

Phase: Phase 1
Intervention: CKD-386(4) F2
Conditions: Hypertension and Dyslipidemia
Sponsor: Chong Kun Dang Pharmaceutical
Enrollment: 31
Locations: 1
Primary Endpoint: Cmax of CKD-386
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-386 in healthy volunteers under fasting conditions.

Detailed Description

To 30 healthy subjects, following treatments are administered dosing in each period and wash-out period is a minimum of 14 days Pharmacokinetic blood samples are collected up to 72hrs. The pharmacokinetic characteristics and safety are assessed.

Registry

clinicaltrials.gov

Start Date

September 23, 2022

End Date

December 12, 2022

Last Updated

3 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Chong Kun Dang Pharmaceutical

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy adults volunteers aged ≥19 years
•Individuals who had 18 kg/m2 ≤ Body Mass Index(BMI) \< 30 kg/m2 and total body weight ≥ 55 kg BMI = Weight(kg)/ Height(m)2
•Following vital signs results at screening
•Systolic blood pressure: 90 mmHg to 139 mmHg
•Diastolic blood pressure: 60 mmHg to 89 mmHg
•Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination
•Individuals who were deemed to be appropriate as study subjects following laboratory tests (hematology, blood chemistry, serology, urology etc.) and ECG etc. performed
•Individuals who agreed proper contraception during the study and did consent to not donation of sperm or eggs 14 days after the last dose of study drug
•Individuals who signed an informed consent form after being fully informed of the study prior to participation, including the objective and content

Exclusion Criteria

•Individuals who had been administered investigational product(s) from other clinical study or bioequivalence study within the 6 months prior to the first administration of investigational drugs
•Those who have used drugs that induce or inhibit drug metabolizing enzymes, such as barbiturates, within 1 month before the first dosing date, or who have used drugs that may interfere with this study within 10 days before the first dosing day (However, clinical investigational drugs) Participation is possible in consideration of pharmacokinetic and pharmacodynamic characteristics such as interaction with concomitant drugs and half-life of concomitant drugs)
•Individuals who donated whole blood within the 8 weeks, or blood components within 4 weeks or had a blood transfusion within 4 weeks prior to the first administration of investigational drugs
•Individuals who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery
•Individuals who meet the following condition with 1 month of the first administration of investigational drugs
•Alcohol: Man-21 glasses/week, Woman-14 glasses/week (1 glass = soju 50mL or liquor 30mL or beer 250mL)
•Smoking: 20 cigarettes/day
•Patients with the following diseases
•Patients with hypersensitivity to the main constituents or components of the investigational drug
•Severe hepatic impairment, biliary atresia or cholestasis